NCT06756269 2025-12-17
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 2 Recruiting
Clinical Trials
6 trialsNCT02520986 2025-08-19
Carbon Dioxide Laser vs. Electrocoagulation for the Therapy of Condyloma
Zydolab - Institute of Cytology and Immune Cytochemistry
Phase NA Recruiting
NCT04422366 2024-06-07
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Recruiting
NCT04895020 2024-04-17
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Recruiting
NCT05027776 2024-04-17
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Recruiting
NCT05371353 2024-04-17
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Shanghai Bovax Biotechnology Co., Ltd.
Recruiting